ChromaDex : Q4 2022 Earnings Presentation

ChromaDex

Earnings Conference Call

Fourth Quarter 2022

Rob Fried

Chief Executive Officer

Brianna Gerber

Chief Financial Officer

Andrew Shao

SVP Scientific & Regulatory Affairs

Nasdaq: CDXC | March 8, 2023

SAFE HARBOR

STATEMENT

This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect the current view about future events. Statements that are not historical in nature, such as 2023 financial outlook, and which may be identified by the use of words like "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could," "predicts," "projects," "continue," "would" or the negative of these terms and other words of similar meaning, are forward-looking statements. Such statements include, but are not limited to, statements contained in this presentation relating to our expected sales, cash flows (including achieving cash flow break-even), planned investments, and financial performance, business, business strategy, expansion, growth, key drivers (including cost savings and increased investments), products and services we recently offered and their impact on our performance or products and services we may offer in the future and the timing of their development, sales and marketing strategy and capital outlook. Forward-looking statements are based on management's current expectations and assumptions regarding our business, the economy and other future conditions and are subject to inherent risks, uncertainties and changes of circumstances that are difficult to predict and may cause actual results to differ materially from those contemplated or expressed. We caution you therefore against relying on any of these forward-looking statements. These risks and uncertainties include those risk factors discussed in Part I, "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities Exchange Commission (the "Commission"), and in subsequent filings with the Commission. Any forward-looking statements are qualified in their entirety by reference to the factors discussed in these filings with the Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Important factors that could cause actual results to differ materially from those in the forward looking statements include but are not limited to: our relationships with major customers; our ability to maintain our sales, marketing, and distribution capabilities; a decline in general economic conditions nationally and internationally; inflationary conditions; the impact of the COVID-19 pandemic on our business and operations, as well as the business or operations of our suppliers, customers, manufacturers, research partners and other third parties with whom we conduct business; the market and size of the vitamin mineral and dietary supplement market; decreased demand for our products and services; market acceptance of our products; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our reliance on of a limited number of third-party party suppliers for certain raw materials; inability to raise capital to fund continuing operations; changes in government regulation; the ability to complete customer transactions and capital raising transactions and other factors relating to our industry, our operations and results of operations.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

About Non-GAAP Financial Measures

ChromaDex's non-GAAP financial measure, Adjusted EBITDA is defined as net income before interest, depreciation, amortization, non-cashshare-based compensation costs, severance and restructuring expense and other income from the Employee Retention Tax Credit. ChromaDex used this non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. This non-GAAP measure should not be viewed in isolation from or as a substitute for ChromaDex's financial results in accordance with GAAP. Reconciliation of this non-GAAP measures to the most directly comparable GAAP measure is attached to this presentation.

FDA Disclaimer

Statements made in this presentation have not been evaluated by the Food and Drug Administration. ChromaDex products are not intended to diagnose, treat, cure, or prevent any disease. The statements in this presentation are for investor relations and educational purposes only and not intended for consumers or vendors.

SAFE HARBOR STATEMENT

2

Q4 2022 & Recent Highlights

• Total company and Tru Niagen® net sales were up 18% and 14% YoY, respectively.
• Delivered on all full year 2022 financial outlook across all metrics, and achieved positive Adjusted EBITDA in the fourth quarter.
• Net loss was $1.4 million or $0.02 loss per share, compared to a net loss of $5.3 million or $0.08 loss per share, in Q4 2021.
• Underlying business, as measured by Adjusted EBITDA(1), delivered a profit of $0.4 million, a $3.8 million improvement, compared to a loss of $3.4 million in Q4 2021.
• Selling and marketing expense as a percentage of net sales was 29.5% versus 48.7% in the prior year quarter, an improvement of 1,920 basis points from Q4 2021, reflecting optimized spending across the organization.
• Delivered a $2.7 million reduction in operating expense from Q4 2021 and gross margin of 57.2%, which was impacted by business mix, as well as overall supply chain cost inflation, partially offset by cost savings initiatives.
• Ended the quarter with $20.4 million in cash. Raised $7.7 million, net of offering costs, with Nestlé Health Science and existing strategic investors in October 2022.
• Granted two new U.S. patents, including one on NRH, which preclinical research suggests may be among the most potent and efficient of the NAD+ precursors, and shows promise as a new therapeutic approach to amelioratingage-related NAD+ decline.
• Continued emphasis on efficiency as we pursue growth opportunities in 2023, while making strategic investments in brand building and R&D to drivelong-term revenue growth and remain a leader in the NAD+ market.

Delivered on business and financial objectives, with an emphasis on bottom line in the current macroeconomic environment. In 2023, expect to make investments in targeted brand building initiatives and R&D to drive future innovation, while continuing to optimize our operations.

(1) See slide 12 for the non-GAAP reconciliation

3

Management Team

Fadi Karam

Chief Marketing Officer

Former Nestlé executive

Deep brand building experience, across traditional retail as well as E-commerce platforms

Rob Fried

Chief Executive Officer

E-commerce & entertainment industry executive

Savoy Pictures, Columbia Pictures, Fried Films, FeeIn, WHN, Healthspan Research

Brianna Gerber

Chief Financial Officer

Over 20 years of diverse experience in investment management and finance at the Capital Group, Mattel, and ChromaDex

Andrew Shao

SVP, Global Regulatory &

Scientific Affairs

Over two decades of global nutrition industry experience at Amway, Herbalife Nutrition, and the Council for Responsible Nutrition.

Heather Van Blarcom

SVP, Legal & Corporate Secretary

Over two decades of industry experience with extensive knowledge of FDA and FTC regulations

4

Financial Highlights